Showing 7371-7380 of 7612 results for "".
- Study Shows No Association Between NSAIDs and BCChttps://practicaldermatology.com/news/20120418-study_shows_no_association_between_nsaids_and_bcc/2459821/New data question an association between NSAID use and development of BCC, showing that NSAID use was not associated with subsequent incidence of BCC (HR = 1.04, 95% CI: 0.92–1.16) after adjusting for age, sex and estimated lifetime summer sun exposure among a cohort of 58,213 Caucasian Radiologic T
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Valeant Headquarters Moving to Montreal Regionhttps://practicaldermatology.com/news/20120416-valeant_headquarters_moving_to_montreal_region/2459825/Valeant Pharmaceuticals is relocating its global headquarters to the Montreal region and will establish the Laboratore Dr. Renaud Centre of Excellence—a R&D center for consumer dermatology—in Laval, Quebec. Laboratoire Dr. Renaud and a newly acqu
- Vichy Partners With timeRAZOR for Free iPhone, Android Apphttps://practicaldermatology.com/news/20120404-vichy_partners_with_timerazor_for_free_iphone_android_app/2459828/With the new timeRAZOR app, Vichy and timeRAZOR help keep users in the know on events occurring close to where they work, live, or plan to be. timeRAZOR pairs technologic components like geolocation with its own Massive Event Selection Engine, i
- Olympic Swimmer Dara Torres Named Brand Ambassador for AmLactinhttps://practicaldermatology.com/news/20120329-olympic_swimmer_dara_torres_named_brand_ambassador_for_amlactin/2459830/AmLactin Alpha-Hydroxy Skin Care is kicking off the new “Ultra Skin Performance” campaign (Upsher-Smith Laboratories, Inc.) and has named 12-time Olympic medalist Dara Torres its first-ever brand ambassador . The “Ultra Skin Performance” campaign educates women of all ages about the internal and ext
- La Roche-Posay Launches Mobile “Dermatologist By Your Side” Educationhttps://practicaldermatology.com/news/20120320-la_roche-posay_launches_mobile_dermatologist_by_your_side_education/2459835/When patients want advice on skin care products in the pharmacy or anywhere, they can dial **DERM from a mobile phone. An automated text response leads them to a dedicated YouTube.com site, featuring educational videos from dermatologists Kavita Mariwala, MD and Shirley Chi, MD. The program from
- EHR iPad App Now Features Speech Recognitionhttps://practicaldermatology.com/news/20120320-ehr_ipad_app_now_features_speech_recognition/2459838/The EZ DERM EHR iPad app is now powered by the cloud-based Nuance Healthcare 360 | Development Platform. The speech recognition platform provides CPU intensive speech and
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Phase 3 Trials launching for adalimumab for hidradenitis suppurativahttps://practicaldermatology.com/news/20120315-phase_3_trials_launching_for_adalimumab_for_hidradenitis_suppurativa/2459842/Two Phase 3 clinical trials are underway to evaluate the safety and efficacy of Abbott's Humira (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS). The